To provide facilities, expertise and capabilities to advance the development of radiation/nuclear medical countermeasures (MCMs) for the mitigation or treatment of acute radiation syndromes/treatment of delayed effects of acute radiation exposure (ARS/DEARE), treatment of internal radionuclide contamination, and support for NIAID's bio dosimetry efforts. The contract will support research and development of radiation and nuclear medical countermeasures towards approval, licensure, or clearance. The supported work will encompass studies performed in the drug development pathway as well as the administrative foundation necessary to facilitate and coordinate these activities in partnership with NIAID. NIAID anticipates that products selected by the government for screening, testing, and development will come from industry, academia (including the NIAID- funded Centers for Medical Countermeasures against Radiation Consortium), and government agencies.